Loading organizations...
iGii, based in Stirling, Scotland, United Kingdom, develops and manufactures Gii™, a patented three-dimensional carbon nanomaterial that combines graphene's properties with scalable production capabilities. The company recently secured a significant £8.8 million in funding, with contributions from the Scottish National Investment Bank, Archangel Investors, and Par Equity, specifically to accelerate manufacturing, R&D, and customer projects. Jean-Christophe Granier was appointed CEO in late 2023 to drive global growth and commercial scaling, leveraging iGii's innovative technology. Co-founded in 2016 by Dr. Marco Caffio and Claus Marquordt, iGii translates cutting-edge research into mass production for critical sectors like healthcare, automotive, and electronics. Its Gii™ technology enables transformative advancements in areas such as electrochemical biosensors, printed batteries, supercapacitors, printed electronics, and at-home diagnostics, having rebranded from Integrated Graphene in 2024 to reflect its unique material.
iGii has raised $15.0M across 2 funding rounds.
iGii has raised $15.0M in total across 2 funding rounds.
iGii has raised $15.0M in total across 2 funding rounds.
iGii's investors include Archangel Investors, Par Equity, Rob Dobson, Techstart Ventures, Vibe Capital, Calum Forsyth.
iGii is a Scotland-based advanced materials company that produces Gii, a pure, porous 3D carbon nanomaterial designed as a high-performance, sustainable alternative to noble metals, printed carbon, and graphene in electrochemical sensing applications.[1][2][4][5] The company primarily serves the biosensor and point-of-care diagnostics markets with Gii-Sens, an ultra-sensitive electrode enabling precise detection of illnesses like cancers, pathogens, and organ failure, while also targeting environmental monitoring, food safety, and animal health testing.[1][2][4][6] It solves key industry challenges by offering superior sensitivity, anti-fouling properties, and scalability at lower costs without supply chain risks or environmental drawbacks, with products integrating into high-throughput manufacturing.[3][4][5] Founded in 2016, iGii has raised approximately $24.68M (with some sources citing $11.2M in recent rounds), employs around 182 people, and reports $55.1M in revenue, showing strong growth momentum through partnerships and reel-to-reel production scaling.[1][3][6]
iGii, originally named RD Graphene and later Integrated Graphene, was founded in 2016 in Stirling, United Kingdom (Scotland), evolving from R&D roots into a commercial advanced materials manufacturer.[1][2] The core innovation emerged from inventing and patenting a rapid manufacturing process to produce Gii, a pure 3D graphene foam, directly on surfaces in seconds, overcoming graphene's scalability hurdles.[2][5][6] A pivotal moment came in November 2020 with the rebranding to Integrated Graphene and launch of Gii-Sens electrodes, marking the shift to market-ready products amid rising demand for point-of-care diagnostics.[2] Early traction built through life science partnerships for lab-on-a-chip assays, bolstered by funding like recent investments from the Scottish National Investment Bank to expand manufacturing.[6] Leadership, including CEO Jean-Christophe Granier, has driven focus on healthcare applications while exploring supercapacitors like Gii-Cap, though medical sensing now dominates.[6]
iGii rides the wave of advanced nanomaterials and sustainable sensing, capitalizing on global demand for point-of-care diagnostics amid post-pandemic health needs, environmental regulations, and green electrification trends.[1][2][4][6] Timing is ideal as traditional materials face supply shortages, rising costs, and ESG scrutiny, while biosensor markets explode for rapid cancer/pathogen testing and food traceability.[4][5][6] Market forces like regulatory pushes for cleaner manufacturing and scalable alternatives favor iGii's carbon-based Gii, which combines graphene's benefits without its flaws, influencing the ecosystem by enabling affordable, high-performance sensors for industries from healthcare to agrotech.[2][5] Backed by Scottish innovation funding, it boosts regional competitiveness and exports nanomaterial breakthroughs worldwide.[6]
iGii is poised to dominate sustainable electrochemical sensing by aggressively scaling reel-to-reel production and deepening healthcare partnerships, potentially expanding Gii-Cap for energy storage if demand resurges.[2][6] Trends like AI-driven diagnostics, stricter ESG mandates, and miniaturized devices will propel growth, with manufacturing investments unlocking global commercial volumes.[3][6] Its influence could evolve from niche innovator to ecosystem enabler, redefining sensor standards and delivering "life-changing benefits for people and our planet" as CEO Granier envisions—transforming costly materials into accessible, high-impact tools.[6] This positions iGii as a cornerstone in the shift to resilient, green tech supply chains, echoing its origins in breakthrough carbon foam invention.[1][2]
iGii has raised $15.0M across 2 funding rounds. Most recently, it raised $11.0M Series U in June 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2024 | $11M Series U | — | Archangel Investors, PAR Equity, ROB Dobson | Announced |
| Nov 1, 2020 | $4M Seed | — | Archangel Investors, PAR Equity, Techstart Ventures, Vibe Capital, Calum Forsyth, ROB Dobson | Announced |